Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01426828 · ClinicalTrials.gov registry record · Phase 2
Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant
A Phase 2 study of Multiple Myeloma, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT01426828: Completed Phase 2 study of Multiple Myeloma, sponsored by University of Pennsylvania.
NCT01426828 is a Phase 2 study of Multiple Myeloma that has completed, run by University of Pennsylvania. The registered enrollment target is 40 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01426828, a Phase 2 study of Multiple Myeloma, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will enroll myeloma subjects undergoing autotransplantation. The primary objective of this study is to evaluate whether infusions of Id-KLH primed CD3/CD28 activated autologous lymphocytes mediate a more intense Id-specific immunity than non Id-KLH primed CD3/CD28 activated autologous lymphocytes. There will be 2 arms in the study, one receiving a DLI with non Id-KLH vaccine and one receiving aDLI with Id-KLH vaccine.
Conditions Studied
Interventions
- BIOLOGICAL CD3/CD28
Study Locations (2)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Texas
- University of Texas, MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-08 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01426828
The ClinicalTrials.gov registry entry for NCT01426828 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which CD3/CD28 is the first listed.
NCT01426828 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT01426828 about?
NCT01426828 is a clinical study titled "Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant". This study will enroll myeloma subjects undergoing autotransplantation. The primary objective of this study is to evaluate whether infusions of Id-KLH primed CD3/CD28 activated autologous lymphocytes mediate a more intense Id-specific immunity than non Id-KLH primed CD3/CD28 activated autologous lym...
What is the current status of trial NCT01426828?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2011-08. Estimated completion is 2017-12.
What conditions does trial NCT01426828 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT01426828?
The interventions under investigation include: CD3/CD28 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01426828?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01426828 being conducted?
This trial has 2 study locations across Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.